[1] L.A. Torre, F. Bray, R.L. Siegel, J. Ferlay, J. Lortet-Tieulent, A. Jemal, Global cancer statistics, 2012, CA Cancer J Clin 65(2) (2015) 87-108.
[2] A. Kinoshita, H. Onoda, N. Fushiya, K. Koike, H. Nishino, H. Tajiri, Staging systems for hepatocellular carcinoma: Current status and future perspectives, World J Hepatol 7(3) (2015) 406-24.
[3] J.P. Wedd, E. Nordstrom, T. Nydam, J. Durham, M. Zimmerman, T. Johnson, W. Thomas Purcell, S.W. Biggins, Hepatocellular carcinoma in patients listed for liver transplantation: Current and future allocation policy and management strategies for the individual patient, Liver Transpl 21(12) (2015) 1543-52.
[4] L.A. Dawson, S. Hashem, A. Bujold, Stereotactic body radiation therapy for hepatocellular carcinoma, Am Soc Clin Oncol Educ Book (2012) 261-4.
[5] M. Scorsetti, T. Comito, L. Cozzi, E. Clerici, A. Tozzi, C. Franzese, P. Navarria, A. Fogliata, S. Tomatis, G. D'Agostino, C. Iftode, P. Mancosu, R. Ceriani, G. Torzilli, The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT), J Cancer Res Clin Oncol 141(7) (2015) 1301-9.
[6] S.M. Yoon, Y.S. Lim, M.J. Park, S.Y. Kim, B. Cho, J.H. Shim, K.M. Kim, H.C. Lee, Y.H. Chung, Y.S. Lee, S.G. Lee, Y.S. Lee, J.H. Park, J.H. Kim, Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma, PLoS One 8(11) (2013) e79854.
[7] J. Sun, T. Zhang, J. Wang, W. Li, A. Zhang, W. He, D. Zhang, D. Li, J. Ding, X. Duan, Biologically effective dose (BED) of stereotactic body radiation therapy (SBRT) was an important factor of therapeutic efficacy in patients with hepatocellular carcinoma (</=5 cm), BMC Cancer 19(1) (2019) 846.
[8] N.D. Parikh, V.D. Marshall, M. Green, T.S. Lawrence, N. Razumilava, D. Owen, A.G. Singal, M. Feng, Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early-stage hepatocellular carcinoma: An analysis of SEER-medicare, J Med Imaging Radiat Oncol 62(5) (2018) 673-681.
[9] K. Shiozawa, M. Watanabe, T. Ikehara, Y. Matsukiyo, M. Kogame, Y. Kishimoto, Y. Okubo, H. Makino, N. Tsukamoto, Y. Igarashi, Y. Sumino, Comparison of percutaneous radiofrequency ablation and CyberKnife((R)) for initial solitary hepatocellular carcinoma: A pilot study, World J Gastroenterol 21(48) (2015) 13490-9.
[10] Z.C. Zeng, J. Seong, S.M. Yoon, J.C. Cheng, K.O. Lam, A.S. Lee, A. Law, J.Y. Zhang, Y. Hu, Consensus on Stereotactic Body Radiation Therapy for Small-Sized Hepatocellular Carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting, Liver Cancer 6(4) (2017) 264-274.
[11] D.F. Stroup, J.A. Berlin, S.C. Morton, I. Olkin, G.D. Williamson, D. Rennie, D. Moher, B.J. Becker, T.A. Sipe, S.B. Thacker, Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group, JAMA 283(15) (2000) 2008-12.
[12] J.F. Tierney, L.A. Stewart, D. Ghersi, S. Burdett, M.R. Sydes, Practical methods for incorporating summary time-to-event data into meta-analysis, Trials 8 (2007) 16.
[13] J.H. Kwon, S.H. Bae, J.Y. Kim, B.O. Choi, H.S. Jang, J.W. Jang, J.Y. Choi, S.K. Yoon, K.W. Chung, Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer, BMC Cancer 10 (2010) 475.
[14] B.G. Jun, Y.D. Kim, G.J. Cheon, E.S. Kim, E. Jwa, S.G. Kim, Y.S. Kim, B.S. Kim, S.W. Jeong, J.Y. Jang, S.H. Lee, H.S. Kim, Clinical significance of radiation-induced liver disease after stereotactic body radiation therapy for hepatocellular carcinoma, Korean J Intern Med 33(6) (2018) 1093-1102.
[15] J. Jung, S.M. Yoon, S.Y. Kim, B. Cho, J.H. Park, S.S. Kim, S.Y. Song, S.W. Lee, S.D. Ahn, E.K. Choi, J.H. Kim, Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters, Radiat Oncol 8 (2013) 249.
[16] Y. Jeong, J. Jung, B. Cho, J. Kwak, C. Jeong, J.H. Kim, J.H. Park, S.Y. Kim, J.H. Shim, K.M. Kim, Y.S. Lim, H.C. Lee, S.M. Yoon, Stereotactic body radiation therapy using a respiratory-gated volumetric-modulated arc therapy technique for small hepatocellular carcinoma, BMC Cancer 18(1) (2018) 416.
[17] S. Balduzzi, G. Rucker, G. Schwarzer, How to perform a meta-analysis with R: a practical tutorial, Evid Based Ment Health 22(4) (2019) 153-160.
[18] B.G. Jun, S.G. Kim, Y.D. Kim, G.J. Cheon, K.H. Han, J.J. Yoo, Y.S. Kim, S.W. Jeong, J.Y. Jang, S.H. Lee, S. Park, H.S. Kim, Combined therapy of transarterial chemoembolization and stereotactic body radiation therapy versus transarterial chemoembolization for </=5cm hepatocellular carcinoma: Propensity score matching analysis, PLoS One 13(10) (2018) e0206381.
[19] T.S. Su, P. Liang, H.Z. Lu, J. Liang, Y.C. Gao, Y. Zhou, Y. Huang, M.Y. Tang, J.N. Liang, Stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma in 132 Chinese patients, J Surg Oncol 113(2) (2016) 181-7.
[20] T. Kimura, H. Aikata, S. Takahashi, I. Takahashi, I. Nishibuchi, Y. Doi, M. Kenjo, Y. Murakami, Y. Honda, H. Kakizawa, K. Awai, K. Chayama, Y. Nagata, Stereotactic body radiotherapy for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies, Hepatol Res 45(4) (2015) 378-86.
[21] N. Sanuki, A. Takeda, Y. Oku, T. Mizuno, Y. Aoki, T. Eriguchi, S. Iwabuchi, E. Kunieda, Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients, Acta Oncol 53(3) (2014) 399-404.
[22] A. Takeda, N. Sanuki, Y. Tsurugai, S. Iwabuchi, K. Matsunaga, H. Ebinuma, K. Imajo, Y. Aoki, H. Saito, E. Kunieda, Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation, Cancer 122(13) (2016) 2041-9.
[23] J.M. Llovet, J. Fuster, J. Bruix, Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation, Hepatology 30(6) (1999) 1434-40.
[24] T. Shibata, H. Isoda, Y. Hirokawa, S. Arizono, K. Shimada, K. Togashi, Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment?, Radiology 252(3) (2009) 905-13.
[25] K.U. Schallreuter, M.A. Gupta, Allergic contact dermatitis from tetrachlordecaoxide (Oxoferin), Contact Dermatitis 17(4) (1987) 253-4.
[26] S. Jonas, W.O. Bechstein, T. Steinmuller, M. Herrmann, C. Radke, T. Berg, U. Settmacher, P. Neuhaus, Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis, Hepatology 33(5) (2001) 1080-6.
[27] S.A. Shah, S.P. Cleary, J.C. Tan, A.C. Wei, S. Gallinger, D.R. Grant, P.D. Greig, An analysis of resection vs transplantation for early hepatocellular carcinoma: defining the optimal therapy at a single institution, Ann Surg Oncol 14(9) (2007) 2608-14.
[28] C.H. Cha, L. Ruo, Y. Fong, W.R. Jarnagin, J. Shia, L.H. Blumgart, R.P. DeMatteo, Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation, Ann Surg 238(3) (2003) 315-21; discussion 321-3.
[29] R.T. Poon, S.T. Fan, C.M. Lo, C.L. Liu, J. Wong, Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation, Ann Surg 235(3) (2002) 373-82.
[30] M.S. Chen, J.Q. Li, Y. Zheng, R.P. Guo, H.H. Liang, Y.Q. Zhang, X.J. Lin, W.Y. Lau, A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma, Ann Surg 243(3) (2006) 321-8.
[31] D.H. Lee, J.M. Lee, J.Y. Lee, S.H. Kim, J.H. Yoon, Y.J. Kim, J.K. Han, B.I. Choi, Radiofrequency ablation of hepatocellular carcinoma as first-line treatment: long-term results and prognostic factors in 162 patients with cirrhosis, Radiology 270(3) (2014) 900-9.
[32] M. Dobrzycka, P. Spychalski, O. Rostkowska, M. Wilczynski, P. Kobiela, M. Grat, V. Dell'Acqua, M. Hoyer, B.A. Jereczek-Fossa, Stereotactic body radiation therapy for early-stage hepatocellular carcinoma - a systematic review on outcome, Acta Oncol 58(12) (2019) 1706-1713.
[33] C.H. Rim, H.J. Kim, J. Seong, Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies, Radiother Oncol 131 (2019) 135-144.
[34] M. Blettner, W. Sauerbrei, B. Schlehofer, T. Scheuchenpflug, C. Friedenreich, Traditional reviews, meta-analyses and pooled analyses in epidemiology, Int J Epidemiol 28(1) (1999) 1-9.
[35] Wells G, Shea B, O’connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. oxford: Ottawa Hospital Research Institute; 2014. ASp; 2015.
[36] Cochran WG. The combination of estimates from different experiments. Biometrics 10 (1954) 101–29.
[37] Egger M, Smith GD, Minder C. Bias in meta-analysis detected by a simple, graphical test-Reply. Brit Med J 316 (1998) 470–1.
[38] Nitin Ohri, Wolfgang A Tomé, Alejandra Méndez Romero, et al. Int J Radiat Oncol Biol Phys S0360-3016(17)(2018) 34525-X.